The core of the pilot line, comprising a Haake twin-screw compounding extruder and Nissei 20T injection molder, enables the production of high-quality drug loaded polymeric devices. This addition gives Particle Sciences the ability to go from bench scale to clinical trial material production.
Particle Sciences has recently completed Phase I of the development of a drug-eluting polymeric vaginal ring that demonstrated 30-day continuous release of a small molecule API.
Andrew Loxley, director of New Technologies, said: “The installation of this line, and our continuing investment in related intellectual property, increases our capabilities, and positions Particle Sciences as an innovative developer of drug-eluting medical devices.”